Reflux Esophagitis (Gastroesophageal Reflux) pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 98 pages | ID: R95EC8FC4F84EN
VPAResearch

Abstracts

2020 Reflux Esophagitis (Gastroesophageal Reflux) PIPELINE HIGHLIGHTS
Reflux Esophagitis (Gastroesophageal Reflux) is one of the widely researched conditions during 2020 with 18 companies actively focusing on realizing pipeline’s potential. Development of Reflux Esophagitis (Gastroesophageal Reflux) medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Reflux Esophagitis (Gastroesophageal Reflux) market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Reflux Esophagitis (Gastroesophageal Reflux).

Good progress is anticipated during 2020 and 2021 with Reflux Esophagitis (Gastroesophageal Reflux) pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Reflux Esophagitis (Gastroesophageal Reflux) pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Reflux Esophagitis (Gastroesophageal Reflux) DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Reflux Esophagitis (Gastroesophageal Reflux) pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Reflux Esophagitis (Gastroesophageal Reflux) pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Reflux Esophagitis (Gastroesophageal Reflux) presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Reflux Esophagitis (Gastroesophageal Reflux) pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Reflux Esophagitis (Gastroesophageal Reflux) DRUG PROFILES
Reflux Esophagitis (Gastroesophageal Reflux) development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Reflux Esophagitis (Gastroesophageal Reflux) COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Reflux Esophagitis (Gastroesophageal Reflux) drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Reflux Esophagitis (Gastroesophageal Reflux). Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 18 Reflux Esophagitis (Gastroesophageal Reflux) companies including company overview, key snapshot, contact information, and their strategies on accelerating Reflux Esophagitis (Gastroesophageal Reflux) pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Ahn-Gook Pharmaceutical Co Ltd, CalyGene Biotechnology Inc, Cancer Advances Inc, Chong Kun Dang Pharmaceutical Corp, Cinclus Pharma AG, CJ HealthCare Corp, Daewoong Pharmaceutical Co , Eisai Co Ltd, Hanmi Pharmaceuticals Co Ltd, Il-Yang Pharm.Co.,Ltd, Ironwood Pharmaceuticals, Jeil Pharmaceutical Co Ltd, RaQualia Pharma Inc, Renexxion LLC , Takeda Pharmaceutical Co, Trio Medicines Ltd, Yooyoung Pharm Co Ltd, Yuyu Pharma Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Reflux Esophagitis (Gastroesophageal Reflux)
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX)

1.1 Reflux Esophagitis (Gastroesophageal Reflux)- Disease overview
1.2 Reflux Esophagitis (Gastroesophageal Reflux)- Market Size
1.3 Reflux Esophagitis (Gastroesophageal Reflux)- Companies Involved

2. REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX) PIPELINE SNAPSHOT- 2020

2.1 Reflux Esophagitis (Gastroesophageal Reflux) Pipeline by Phase
2.2 Reflux Esophagitis (Gastroesophageal Reflux) Pipeline by Mechanism of Action
2.3 Reflux Esophagitis (Gastroesophageal Reflux) Pipeline by Route of Administration
2.4 Reflux Esophagitis (Gastroesophageal Reflux) Pipeline- New Molecular Entities
2.5 Reflux Esophagitis (Gastroesophageal Reflux) Pipeline- Orphan Drug Designation/ Special Designation

3. REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX) DRUG PROFILES

3.1 Current Status
3.2 Reflux Esophagitis (Gastroesophageal Reflux) Drug Snapshot
3.3 Reflux Esophagitis (Gastroesophageal Reflux) Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Ahn-Gook Pharmaceutical Co Ltd Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.2 CalyGene Biotechnology Inc Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.3 Cancer Advances Inc Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.4 Chong Kun Dang Pharmaceutical Corp Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.5 Cinclus Pharma AG Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.6 CJ HealthCare Corp Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.7 Daewoong Pharmaceutical Co Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.8 Eisai Co Ltd Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.9 Hanmi Pharmaceuticals Co Ltd Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.10 Il-Yang Pharm.Co.,Ltd Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.11 Ironwood Pharmaceuticals Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.12 Jeil Pharmaceutical Co Ltd Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.13 RaQualia Pharma Inc Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.14 Renexxion LLC Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.15 Takeda Pharmaceutical Co Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.16 Trio Medicines Ltd Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.17 Yooyoung Pharm Co Ltd Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials
4.18 Yuyu Pharma Inc Reflux Esophagitis (Gastroesophageal Reflux) Pipeline Insights and Clinical Trials

5. REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX) MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information